Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability

Mirati Therapeutics is looking to a KRAS-Keytruda combination to give it an edge over Amgen in lung cancer. After lowering the dose of its KRAS drug, Mirati saw around 60% of first-line patients respond to the combination—and lessened the tolerability concerns that initially held back the cocktail.